Description
What BIKTARVY vedotin is?
BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of
treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY. Biktarvy is an example of a combination drug that can be taken as a complete regimen for treatment of the human immunodeficiency virus.
What Bictegravir/emtricitabine/tenofovir alafenamide is?
Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed dose combination drug for the treatment of HIV/AIDS. It contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[2] It was approved for use in the United States in February 2018. It was approved for use in the European Union in June 2018.
